FDA Approves Unknown Drug — HIKMA

HIKMA announced the approval of an ANDA by the FDA on September 23, 2011, which is expected to bolster the company's generic portfolio and provide incremental revenue opportunities. Market participants will view this clearance as a positive factor in HIKMA's long-term growth strategy, particularly as the drug generates significant annual sales.